Page 1092 - Hematology_ Basic Principles and Practice ( PDFDrive )

969.e6 Part VII Hematologic Malignancies

229. Parker JE, Fishlock KL, Mijovic A, et al: Low-risk” myelodysplastic 251. Chanarin I: Megaloblastic anaemia, cobalamin, and folate. J Clin Pathol
syndrome is associated with excessive apoptosis and an increased ratio 40(9):978–984, 1987.
of pro- versus anti-apoptotic bcl-2-related proteins. Br J Haematol 252. Aitelli C, Wasson L, Page R: Pernicious anemia: presentations mimick-
103(4):1075–1082, 1998. ing acute leukemia. South Med J 97(3):295–297, 2004.
230. Letai A: Restoring cancer’s death sentence. Cancer Cell 10(5):343–345, 253. Stabler SP: Clinical practice. Vitamin B12 deficiency. N Engl J Med
2006. 368(2):149–160, 2013.
231. Reza S, Shetty V, Dar S, et al: Tumor necrosis factor-alpha levels 254. Balsa JA, Botella-Carretero JI, Gómez-Martín JM, et al: Copper and
decrease with anticytokine therapy in patients with myelodysplastic zinc serum levels after derivative bariatric surgery: differences between
syndromes. J Interferon Cytokine Res 18(10):871–877, 1998. Roux-en-Y Gastric bypass and biliopancreatic diversion. Obes Surg
232. Shetty V, Mundle S, Alvi S, et al: Measurement of apoptosis, prolifera- 21(6):744–750, 2011.
tion and three cytokines in 46 patients with myelodysplastic syndromes. 255. Fiske DN, McCoy HE, Kitchens CS: Zinc-induced sideroblastic
Leuk Res 20(11–12):891–900, 1996. anemia: report of a case, review of the literature, and description of
233. Letai AG: Diagnosing and exploiting cancer’s addiction to blocks in the hematologic syndrome. Am J Hematol 46(2):147–150, 1994.
apoptosis. Nat Rev Cancer 8(2):121–132, 2008. 256. Halfdanarson TR, Kumar N, Li C-Y, et al: Hematological manifes-
234. Parker JE, Mufti GJ, Rasool F, et al: The role of apoptosis, proliferation, tations of copper deficiency: a retrospective review. Eur J Haematol
and the Bcl-2-related proteins in the myelodysplastic syndromes and 80(6):523–531, 2008.
acute myeloid leukemia secondary to MDS. Blood 96(12):3932–3938, 257. Imataki O, Ohnishi H, Kitanaka A, et al: Pancytopenia complicated
2000. with peripheral neuropathy due to copper deficiency: clinical diagnostic
235. Slape CI, Saw J, Jowett JBM, et al: Inhibition of apoptosis by BCL2 review. Intern Med 47(23):2063–2065, 2008.
prevents leukemic transformation of a murine myelodysplastic syn- 258. Huff JD, Keung Y-K, Thakuri M, et al: Copper deficiency causes revers-
drome. Blood 120(12):2475–2483, 2012. ible myelodysplasia. Am J Hematol 82(7):625–630, 2007.
236. Beurlet S, Omidvar N, Gorombei P, et al: BCL-2 inhibition with 259. Chanarin I: Alcohol and haemopoiesis. Br J Haematol 17(6):515–516,
ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML 1969.
by targeting primitive LSK and progenitor cells. Blood 122(16):2864– 260. Scott JM, Weir DG: Drug-induced megaloblastic change. Clin Haema-
2876, 2013. tol 9(3):587–606, 1980.
237. Bogenberger JM, Kornblau SM, Pierceall WE, et al: BCL-2 family pro- 261. Hongeng S, May W, Crist WM: Transient myeloid dysplasia due to
teins as 5-Azacytidine-sensitizing targets and determinants of response valproic acid. Clin Pediatr (Phila) 36(6):361–364, 1997.
in myeloid malignancies. Leukemia 28(8):1657–1665, 2014. 262. Kennedy GA, Kay TD, Johnson DW, et al: Neutrophil dysplasia char-
238. Takahashi K, Jabbour E, Wang X, et al: Dynamic acquisition of FLT3 acterised by a pseudo-Pelger-Huet anomaly occurring with the use of
or RAS alterations drive a subset of patients with lower risk MDS to mycophenolate mofetil and ganciclovir following renal transplantation:
secondary AML. Leukemia 27(10):2081–2083, 2013. a report of five cases. Pathology (Phila) 34(3):263–266, 2002.
239. Murphy DM, Bejar R, Stevenson K, et al: NRAS mutations with low 263. Taegtmeyer AB, Halil O, Bell AD, et al: Neutrophil dysplasia (acquired
allele burden have independent prognostic significance for patients with pseudo-pelger anomaly) caused by ganciclovir. Transplantation 80(1):
lower risk myelodysplastic syndromes. Leukemia 27(10):2077–2081, 127–130, 2005.
2013. 264. Gibbs SDJ, Westerman DA, McCormack C, et al: Severe and pro-
240. Lorenzo F, Nishii K, Monma F, et al: Mutational analysis of the KIT longed myeloid haematopoietic toxicity with myelodysplastic features
gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. following alemtuzumab therapy in patients with peripheral T-cell
Leuk Res 30(10):1235–1239, 2006. lymphoproliferative disorders. Br J Haematol 130(1):87–91, 2005.
241. Kaeferstein A, Krug U, Tiesmeier J, et al: The emergence of a C/ 265. Frewin RJ, Provan D, Smith AG: Myelodysplasia occurring after
EBPalpha mutation in the clonal evolution of MDS towards secondary fludarabine treatment for chronic lymphocytic leukaemia. Clin Lab
AML. Leukemia 17(2):343–349, 2003. Haematol 19(2):151–152, 1997.
242. Pagano L, Pulsoni A, Vignetti M, et al: Secondary acute myeloid 266. Buchbinder R, Hall S, Ryan PF, et al: Severe bone marrow failure due
leukaemia: results of conventional treatments. Experience of GIMEMA to low dose oral methotrexate. J Rheumatol 15(10):1586–1588, 1988.
trials. Ann Oncol 16(2):228–233, 2005. 267. Piso RJ, Kriz K, Desax M-C: Severe isoniazid related sideroblastic
243. Leone G, Mele L, Pulsoni A, et al: The incidence of secondary leuke- anemia. Hematol Rep 3(1):e2, 2011.
mias. Haematologica 84(10):937–945, 1999. 268. Beck EA, Ziegler G, Schmid R, et al: Reversible sideroblastic anemia
244. Gerstung M, Pellagatti A, Malcovati L, et al: Combining gene mutation caused by chloramphenicol. Acta Haematol 38(1):1–10, 1967.
with gene expression data improves outcome prediction in myelodys- 269. Verwilghen R, Reybrouck G, Callens L, et al: Antituberculous drugs
plastic syndromes. Nat Commun 6:5901, 2015. and sideroblastic anaemia. Br J Haematol 11:92–98, 1965.
245. Kobayashi Y, Nakayama M, Uemura N, et al: Analysis of myelo- 270. Colucci G, Silzle T, Solenthaler M: Pyrazinamide-induced sideroblastic
dysplastic syndrome clones arising after multiple myeloma: a case anemia. Am J Hematol 87(3):305, 2012.
study by correlative interphase cytogenetic analysis. Jpn J Clin Oncol 271. Haden HT: Pyridoxine-responsive sideroblastic anemia due to antitu-
29(8):374–377, 1999. berculous drugs. Arch Intern Med 120(5):602–606, 1967.
246. Lorand-Metze I, Lima CS, Cardinalli IA, et al: Association of a 272. Scott J, Finegold S, Belkin G, et al: A controlled double-blind
myelodysplastic syndrome with hairy cell leukaemia. Eur J Haematol study of the hematologic toxicity of chloramphenicol. N Engl J Med
55(5):341–343, 1995. 272:1137–1142, 1965.
247. Mitterbauer G, Schwarzmeier J, Mitterbauer M, et al: Myelodysplastic 273. Karcher DS, Frost AR: The bone marrow in human immunodeficiency
syndrome/acute myeloid leukemia supervening previously untreated virus (HIV)-related disease. Morphology and clinical correlation. Am J
chronic B-lymphocytic leukemia: demonstration of the concomitant Clin Pathol 95(1):63–71, 1991.
presence of two different malignant clones by immunologic and 274. Scadden DT, Zon LI, Groopman JE: Pathophysiology and management
molecular analysis. Ann Hematol 74(4):193–197, 1997. of HIV-associated hematologic disorders. Blood 74(5):1455–1463,
248. Wells DA, Hall MC, Shulman HM, et al: Occult B cell malignan- 1989.
cies can be detected by three-color flow cytometry in patients with 275. Recommendation Summary - US Preventive Services Task Force
cytopenias. Leukemia 12(12):2015–2023, 1998. [Internet]. [cited 2015 Mar 17];Available from: <http://www
249. Saunthararajah Y, Molldrem JL, Rivera M, et al: Coincident myelodys- .uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/
plastic syndrome and T-cell large granular lymphocytic disease: clinical human-immunodeficiency-virus-hiv-infection-screening>.
and pathophysiological features. Br J Haematol 112(1):195–200, 2001. 276. Kasahara S, Hara T, Itoh H, et al: Hypoplastic myelodysplastic syn-
250. Steensma DP: Dysplasia has A differential diagnosis: distinguishing dromes can be distinguished from acquired aplastic anaemia by bone
genuine myelodysplastic syndromes (MDS) from mimics, imitators, marrow stem cell expression of the tumour necrosis factor receptor. Br
copycats and impostors. Curr Hematol Malig Rep 7(4):310–320, 2012. J Haematol 118(1):181–188, 2002.